Bromide

Bromide

SCHEMBL4287071

Sc1ccccc1C[P+](c1ccccc1)(c1ccccc1)c1ccccc1.[Br-]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.46
SNCA P37840 2/20 0.44
CYP1A2 P05177 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
MMP1 P03956 2/20 0.32
MAPT P10636 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
FOLH1 Q04609 2/20 0.31
APP P05067 1/20 0.31
CPA3 P15088 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2446627 0.86 HIF1A (0.55) HIF1ASNCACYP1A2ALDH1A1CYP2D6
Hydrochloric Acid SCHEMBL9292231 0.81 HIF1A (0.55) HIF1ASNCACYP1A2ALDH1A1CYP2D6
Bromide SCHEMBL8464686 0.80 HIF1A (0.48) HIF1ASNCACYP1A2ALDH1A1CYP2D6
Bromide SCHEMBL4293626 0.80 SNCA (0.37) HIF1ASNCACYP1A2ALDH1A1CYP2D6
Bromide SCHEMBL4297579 0.80 SNCA (0.37) HIF1ASNCACYP1A2ALDH1A1CYP2D6
Bromide SCHEMBL4182972 0.78 CTNNB1 (0.47) HIF1ASNCACYP1A2CYP2D6CYP2C19
Bromide SCHEMBL1465677 0.77 HIF1A (0.44) HIF1ASNCACYP1A2ALDH1A1CYP2D6
Bromide SCHEMBL4175689 0.77 HIF1A (0.44) HIF1ASNCACYP1A2ALDH1A1CYP2D6
Bromide SCHEMBL898427 0.77 HSPA5 (0.48) HIF1ASNCACYP1A2ALDH1A1CYP2D6
Bromide SCHEMBL1957564 0.77 HIF1A (0.44) HIF1ASNCACYP1A2ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20080299041-A1 HETEROCYCLIC INDENE DERIVATIVES AND THEIR RADIOISOTOPE LABELED COMPOUNDS FOR IMAGING BETA-AMYLOID DEPOSITION SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2008-12-04 US disclosed
EP-1971596-A2 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS Takeda Pharmaceutical Company Limited (JP) 2008-09-24 EP disclosed
WO-2007077961-A2 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands NR3C2, NR3C1, MC2R HIF1A 3046/4885SNCA 4830/4885CYP1A2 438/4885
US-20080299041-A1 HETEROCYCLIC INDENE DERIVATIVES AND THEIR RADIOISOTOPE LABELED COMPOUNDS FOR IMAGING BETA-AMYLOID DEPOSITION APP, BACE1, PSEN1 HIF1A 1822/4885SNCA 20/4885CYP1A2 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.